Marksans Pharma Q2 Results
- BSE: 524404
- NSE: MARKSANS
- ISIN: INE750C01026
- Sector: Biotechnology & Drugs
BSE
171.15
-2.50 (-1.44%)
-2.50 (-1.44%)Volume24.27 K
Updated: Fri 6 Mar, 2026 | 15:53:14
NSE
171.05-2.77 (-1.59%)
-2.77 (-1.59%)Volume4.54 L
Updated: Fri 6 Mar, 2026 | 15:44:11
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - Marksans Pharma Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 602.83 | 542.97 | 11.03% | 525.75 | 14.66% |
| Depreciation/ Amortization | 26.92 | 23.10 | 16.51% | 19.51 | 37.96% |
| Operating Income | 117.58 | 77.02 | 52.65% | 116.17 | 1.21% |
| Net Income | 98.25 | 58.32 | 68.48% | 96.72 | 1.59% |
| Other Operating Expenses Total | 163.52 | 159.67 | 2.41% | 163.69 | -0.10% |
| Net Income Before Taxes | 133.33 | 76.60 | 74.07% | 124.60 | 7.01% |
| Total Revenue | 720.41 | 619.99 | 16.20% | 641.92 | 12.23% |
| Selling/ General/ Admin Expenses Total | 103.80 | 98.39 | 5.51% | 84.16 | 23.35% |
| Diluted Normalized EPS | 2.17 | 1.29 | 68.22% | 2.13 | 1.88% |